Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis
原文： 2022 年 发布于
European Urology
17 卷 第 4 期 1040-1055
浏览量：220次
作者：
Daryanto B.
Purnomo A. F.
Seputra K. P.
Budaya T. N.
作者单位：
Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Universiteitssingel 40 (Room C5.570), 6229 ER, Maastricht, The Netherlands. Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Universiteitssingel 40 (Room C5.570), 6229 ER, Maastricht, The Netherlands. anke.wesselius@maastrichtuniversity.nl. Department of Clinical Studies and Nutritional Epidemiology, Nutrition Biomed Research Institute, Melbourne, Australia. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia. Department of Epidemiology, Schools for Oncology and Developmental Biology and Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands. Department of Epidemiology Radiation Effects Research Foundation, Hiroshima, Japan. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. International Agency for Research on Cancer World Health Organization, Lyon, France. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Department for Determinants of Chronic Diseases, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Escuela Andaluza de Salud Publia, Granada, Spain. Instituto de Investigación Biosanitaria, Granada, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain. Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands. School of Cancer Sciences, University of Birmingham, Birmingham, UK.
归属分类：
膀胱肿瘤治疗及预后证据
DOI：
10.1016/j.euf.2021.05.005
关键词：
Cystectomy/*methods
Electrosurgery/*methods
Humans
Neoplasm Invasiveness
Urethra
Urinary Bladder Neoplasms/pathology/*surgery
Bipolar
Meta-analysis
Monopolar
Non-muscle invasive bladder cancer
Transurethral resection
Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle invasive cancer patients require conservative local treatment, while the remaining 25% of patients undergo radical cystectomy or radiotherapy. Immune checkpoint inhibitors represent a novel class of immunotherapy drugs that restore natural antitumoral immune activity via the blockage of inhibitory receptors and ligands expressed on antigen-presenting cells, T lymphocytes and tumour cells. The use of immune checkpoint inhibitors in bladder cancer has been expanded from the neoadjuvant setting, i.e., after radical cystectomy, to the adjuvant setting, i.e., before the operative time or chemotherapy, in order to improve the overall survival and to reduce the morbidity and mortality of both the disease and its treatment. However, some patients do not respond to checkpoint inhibitors. As result, the capability for identifying patients that are eligible for this immunotherapy represent one of the efforts of ongoing studies. The aim of this systematic review is to summarize the most recent evidence regarding the use of immune checkpoint inhibitors, in a neoadjuvant and adjuvant setting, in the treatment of muscle-invasive bladder cancer.